Expect Pfizer to focus on more oncology opportunities following off-patent drug purge
After $12 billion Upjohn deal with Mylan, CEO Bourla says company is on the hunt for early- and mid-stage cancer assets
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.